Ricerca e sviluppo
Recordati è dedita ad un’attività continuativa di sviluppo di nuovi prodotti specialistici, sia internamente che tramite collaborazioni di sviluppo con altre aziende farmaceutiche e istituti di ricerca.
La devozione al rigore scientifico, le competenze e il personale altamente specializzato consentono al gruppo di sviluppare nuove opzioni terapeutiche e di avere sempre in cantiere idee per prodotti innovativi.
Life Cycle Management
Products
Originator
Name
Therapeutic area
Development Stage
Discover/
Preclinical
Proof of
Concept
Late
Stage
Registration
Post
Marketing
Originator:
Recordati
Molecule Name:
CARBAGLU®
Therapeautic Area:
Metabolic and other
Hyperammonaemia due to NAGS deficiency and to the main organic acidaemias
Phase/Status:
Registration
Development Details:
Regulatory Approval obtained in China in NAGS deficiency and organic acidaemias
Originator:
Recordati
Molecule Name:
CYSTADROPS®
Therapeautic Area:
Metabolic and other
Corneal cystine crystal deposits in patients with cystinosis
Phase/Status:
Late Stage
Development Details:
New Container Closure System
Originator:
Tolmar
Molecule Name:
ELIGARD®
Therapeautic Area:
SPC
Hormone-dependent prostate cancer
Phase/Status:
Late Stage
Development Details:
New device post-approval activities
Originator:
Novartis / Recordati
Molecule Name:
ISTURISA®*
Therapeautic Area:
Endocrinology
Endogenous Cushing's syndrome/Cushing's disease
Phase/Status:
Late Stage
Development Details:
Real World Evidence (LINC-7)
Originator:
Apeiron / Recordati
Molecule Name:
QARZIBA®*
Therapeautic Area:
Oncology
Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma
Phase/Status:
Late Stage
Development Details:
Relapsed/Refractory Induction
Originator:
Apeiron / Recordati
Molecule Name:
QARZIBA®
Therapeautic Area:
Oncology
Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma
Phase/Status:
Late Stage
Development Details:
Frontline Induction
Originator:
Novartis / Recordati
Molecule Name:
SIGNIFOR®*
Therapeautic Area:
Endocrinology
Post-Bariatric Hypoglycaemia
Phase/Status:
Proof of Concept
Development Details:
Phase II
Originator:
Recordati
Molecule Name:
SYLVANT®*
Therapeautic Area:
Oncology
IL-6 induced diseases
Phase/Status:
Proof of Concept
Development Details:
CRS/ICANs
Products
Originator
Molecule Name
Therapeutic area
Development Stage
Discover/
Preclinical
Proof of
Concept
Late
Stage
Registration
Post
Marketing
Originator:
Recordati / AP-HP
Molecule Name:
REC 0545 / MAAPLIV*
Therapeautic Area:
Metabolic and other
Acute decompensation episodes in Maple Syrup Urine Disease (MSUD) or leucinosis
Phase/Status:
Registration
Development Details:
Registration stage ongoing. Filing in EU done in 2023
Originator:
Recordati / MimeTech
Molecule Name:
REC 0559*
Therapeautic Area:
Metabolic and other
Neurotrophic Keratitis
Phase/Status:
Proof of Concept
Development Details:
Phase 2 in progress
Products
Originator
Molecule Name
Therapeutic area
Development Stage
Discover/
Preclinical
Proof of
Concept
Late
Stage
Registration
Post
Marketing
Originator:
Novartis / Recordati
Molecule Name:
ISTURISA®
Therapeautic Area:
Endocrinology
Endogenous Cushing's syndrome/Cushing's disease
Phase/Status:
Post Marketing
Development Details:
Non-Interventional Study (LINC-6)
Originator:
Novartis / Recordati
Molecule Name:
ISTURISA®
Therapeautic Area:
Endocrinology
Endogenous Cushing's syndrome/ Cushing's disease
Phase/Status:
Post Marketing
Development Details:
Paediatric post-approval development plan
Originator:
Gedeon Richter
Molecule Name:
REAGLIA®
Therapeautic Area:
CNS
Schizophrenia
Phase/Status:
Post Marketing
Development Details:
Post marketing regulation
*= will result in new product indication
La struttura di Recordati è unica, con opportunità in tutti i team di ricerca e sviluppo, inclusi CMC, pre-clinico, regolatorio, della farmacovigilanza, del controllo della qualità, delle operazioni cliniche, dello sviluppo clinico e il team medico. Siamo in continua crescita, e i nostri obiettivi sono incentrati sullo sviluppo di nuovi prodotti specialistici, nuove opzioni terapeutiche e sull’investimento nelle innovazioni mediche che possano offrire un futuro migliore.
Sei interessato/a a unirti al team?
Promuoviamo una cultura imprenditoriale, dove coloro che svolgono prestazioni ad elevata efficienza godono della possibilità e del nostro supporto per fare la differenza nella nostra organizzazione.